ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Miscellaneous Rheumatic and Inflammatory Diseases Poster I: Checkpoint Inhibitors, Retroperitoneal Fibrosis

Date: Sunday, October 21, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM
Abstract Number: 372
Arterial Involvement in Erdheim-Chester Disease: A Retrospective Cohort Study
9:00AM-11:00AM
Abstract Number: 355
Association of HLA-DRB1 Shared Epitope Alleles with Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
9:00AM-11:00AM
Abstract Number: 369
Association of Retroperitoneal Fibrosis with Malignancy and the Pathologic Features of Malignancy with Retroperitoneal Fibrosis
9:00AM-11:00AM
Abstract Number: 359
Characterization of Lymphoid Cells in Synovial Fluid from Cancer Patients with Immunotherapy-Induced Arthritis
9:00AM-11:00AM
Abstract Number: 350
Clinical Correlates of Immune-Related Adverse Events for Patients with Melanoma Treated with Checkpoint Inhibitors and a Noted Significant Difference in Peripheral Lymphocyte Counts
9:00AM-11:00AM
Abstract Number: 364
Elevated sCD40L As a Predictive Biomarker of Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
9:00AM-11:00AM
Abstract Number: 362
Immune Check Point Inhibitors, Auto-Antibodies, and Immune Adverse Reactions
9:00AM-11:00AM
Abstract Number: 356
Immune Related Adverse Events from Immune Checkpoint Inhibitors: A Retrospective Analysis from 2004-2017 at the University of North Carolina at Chapel Hill
9:00AM-11:00AM
Abstract Number: 353
Immune-Related Adverse Events Associated with Immunotherapy in Solid Organ Tumors. Study of 102 Cases from a Referral Single Center for Last 3 Years
9:00AM-11:00AM
Abstract Number: 363
Immune-Related Adverse Events in Cancer Immunotherapy: How Often Do We See Them?
9:00AM-11:00AM
Abstract Number: 358
Immunophenotypic Analysis of T Cells from Leukemia Patients with Immune Checkpoint Inhibitor-Associated Respiratory Complications
9:00AM-11:00AM
Abstract Number: 367
Incidence of Inflammatory Bowel Disease (IBD) Among Patients (Pts) with Other Chronic Inflammatory Diseases (CID) Treated with Interleukin-17a (IL-17a) or Phosphodiesterase 4 (PDE4) Inhibitors
9:00AM-11:00AM
Abstract Number: 366
Infectious Complications of Immunosuppressive Therapy in Patients with Common Variable Immunodeficiency (CVID) and Inflammatory Arthritis
9:00AM-11:00AM
Abstract Number: 365
Monoclonal Gammopathy in Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 357
Musculoskeletal Immune-Related Adverse Events with Use of Checkpoint Inhibitors in Malignancy: Experience in Sydney, Australia
9:00AM-11:00AM
Abstract Number: 352
Polymyalgia Rheumatica-like Syndrome from Checkpoint Inhibitor Therapy: Case Series and Systematic Review of the Literature
9:00AM-11:00AM
Abstract Number: 354
Rheumatic Complications of Immune Checkpoint Inhibitor Therapy: A Single Center Experience
9:00AM-11:00AM
Abstract Number: 351
Rheumatic Immune-Related Adverse Events in Patients on ANTI-PD-1 Inhibitors: Fasciitis with Myositis Syndrome As a New Rheumatic Complication of Immunotherapy
9:00AM-11:00AM
Abstract Number: 361
Risk Factors of Immune-Related Adverse Events in Patients Treated with Anti-Programmed Cell Death 1 Antibody Pembrolizumab
9:00AM-11:00AM
Abstract Number: 370
Rituximab in Idiopathic Retroperitoneal Fibrosis
9:00AM-11:00AM
Abstract Number: 360
Sarcoidosis Induced By Immune Check Point Inhibitors
9:00AM-11:00AM
Abstract Number: 368
Synovianalysis Using Leukocyte Esterase Reagent Strips
9:00AM-11:00AM
Abstract Number: 371
Therapeutic Efficacy and Safety of Iguratimod in Treating Mild IgG4-Related Diseases

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology